Pharmacological Profile and Effects on Blood
The drug has been used in medicine since 1979. Its primary feature is a comprehensive impact on blood rheological properties (fluidity). Ticlopidine not only acts as a classical antiplatelet agent, preventing thrombus formation, but also exerts a marked effect on red blood cells (erythrocytes). Under the drug's influence, their deformability increases, allowing cells to pass more easily through narrow capillaries. Simultaneously, erythrocyte aggregation is reduced, reliably lowering overall blood viscosity.
It is important to consider that the therapeutic effect does not develop immediately. The effect builds up gradually, and maximal antiplatelet activity is achieved only after 4–7 days of regular administration.
Pharmacokinetics: Absorption, Metabolism, and Excretion
The drug has high oral bioavailability ranging from 80% to 90%. Notably, the presence of food in the stomach not only does not hinder absorption but increases it by 10–20%. Once in the bloodstream, the drug actively binds to plasma proteins.
Ticlopidine is extensively metabolized in the liver. Biotransformation yields four distinct metabolites, yet only one possesses antiplatelet activity.
The elimination process has unique features. With prolonged use, drug accumulation occurs in the body, leading to a significant prolongation of the elimination half-life ($T_{1/2}$):
- After a single dose, it is approximately 13 hours.
- During chronic therapy, it increases to 4–5 days.
Clinical Indications and Dosage Regimen
In clinical practice, the drug is prescribed for major vascular conditions. Key indications include:
- Secondary prevention of ischemic stroke.
- Prevention of thrombosis in patients with peripheral artery disease.
- Treatment of diabetic microangiopathy.
- Prevention of thromboembolism during cardiac surgery procedures such as coronary artery bypass graft (CABG) and coronary stenting.
The standard dosing regimen involves oral administration twice daily with meals. Because the onset of action is slow, therapy is often initiated with a loading dose of 500 mg to achieve rapid clinical efficacy.
Adverse Effects and Strict Limitations
The widespread use of the drug is limited by its safety profile. The gastrointestinal tract is most frequently affected: up to 20% of patients develop diarrhea, and decreased appetite, nausea, vomiting, and abdominal pain are also reported. Skin rashes occur in 11–14% of patients.
Laboratory tests may show elevated levels of atherogenic lipoproteins, as well as increased activity of liver enzymes (transaminases and alkaline phosphatase). Like all antiplatelet agents, the drug increases overall bleeding tendency.
Hematological toxicity is the most dangerous group of complications.
- Neutropenia: occurs in 1–2.4% of patients. The risk is highest during the first 3 months of therapy.
- Other severe disorders such as thrombocytopenia and agranulocytosis are possible.
- Rare but life-threatening complications include aplastic anemia.
Due to the high risk of hematological reactions, patient management requires mandatory regular monitoring of blood counts (complete blood count) throughout the first months of treatment.